FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer

Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority ... Read More